Pharmacokinetics and metabolomics of the new psychoactive substance 4-chloroethylcathinone

被引:4
|
作者
Wang, Yong [1 ,2 ]
Yang, Ying [3 ]
Zhan, Yujuan [3 ]
Yin, Jun [3 ]
Zhou, Xueting [3 ]
Xu, Chen [3 ]
Gao, Feiyu [3 ]
Liu, Junning [2 ]
Wu, Chunyong [3 ]
Liu, Songqin [1 ]
Zhang, Junying [4 ]
Shu, Chang [3 ]
机构
[1] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Peoples R China
[2] Nanjing Publ Secur Bur, Inst Forens Sci & Technol, Nanjing 210001, Peoples R China
[3] China Pharmaceut Univ, Dept Pharmaceut Anal, Nanjing 211198, Peoples R China
[4] China Pharmaceut Univ, Dept Tradit Chinese Med, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
4-Chloroethylcathinone; New psychoactive substance; Pharmacokinetics; Untargeted metabolomics; MICE;
D O I
10.1016/j.arabjc.2023.105039
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Synthetic 4-Chloroethcathinone (4-CEC) is a derivative of cathinone that belongs to one of the more severe abused substances among new psychoactive substances (NPS). Current researches on 4-CEC mainly focus on metabolite identification studies, and there is a lack of researches on phar-macokinetic, tissue distribution and metabolomics studies in vivo. A sensitive and reliable LC-MS/ MS assay was developed and validated for the determination of 4-CEC concentrations in plasma and tissue homogenates. According to the pharmacokinetic results, the absorption and elimination of 4-CEC were faster after administration. The Cmax was 1896 & PLUSMN; 876 ng/ml, the peak time Tmax was 10.1 & PLUSMN; 9.2 min, and the elimination half-life t1/2 was 100.4 min. Metabolomics studies showed that the highest concentrations of 4-CEC were found in brain, lung, kidney and liver. The results of tissue biopsy showed that the liver, kidney and brain tissue had a certain degree of damage. After 4-CEC administration, amino acid-related metabolism and biosynthesis, lipid metabolism, niacin and niaci-namide metabolism in mice were interfered, suggesting that 4-CEC could cause energy metabolism disorder in mice. The metabolic pathways and toxicity mechanisms related to 4-CEC entry into the body were explained at the overall metabolic level by multivariate data analysis, screening and iden-tification of differential metabolites and metabolic pathway analysis.& COPY; 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Reported recreational drug and new psychoactive substance use versus laboratory detection of substances by high-resolution mass spectrometry in patients presenting to an emergency department in London with acute drug toxicity
    Wolfe, Caitlin E.
    Rowe, Ashley
    Hudson, Simon
    Archer, John R. H.
    Dargan, Paul I.
    Wood, David M.
    CLINICAL TOXICOLOGY, 2024, 62 (11) : 693 - 697
  • [32] A new functional CYP3A4 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients
    Elens, L.
    Bouamar, R.
    Hesselink, D.
    Haufroid, V
    van der Heiden, I
    van Gelder, T.
    van Schaik, R.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 507 - 507
  • [33] STUDY OF THE NEW 4-PHENYLPYRROLIDINONE-2 DERIVATIVE PHARMACOKINETICS AND NEUROPROTECTIVE EFFECT IN THE ISCHEMIC STROKE ANIMAL MODEL
    Borozdenko, D. A.
    Lyakhmun, D. N.
    Golubev, Ya, V
    Tarasenko, D., V
    Kiseleva, N. M.
    Negrebetsky, Vad V.
    BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2020, (01): : 51 - 58
  • [34] LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques
    Achim T. Caspar
    Folker Westphal
    Markus R. Meyer
    Hans H. Maurer
    Analytical and Bioanalytical Chemistry, 2018, 410 : 897 - 912
  • [35] New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans
    Merali, Samira
    Wang, Zhaoqing
    Frost, Charles
    Callejo, Mario
    Hedrick, Michael
    Hui, Lester
    Shropshire, Stephanie Meadows
    Xu, Ke
    Bouvier, Michel
    DeSouza, Mary M.
    Yang, Jing
    PLATELETS, 2022, 33 (07) : 969 - 978
  • [36] LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques
    Caspar, Achim T.
    Westphal, Folker
    Meyer, Markus R.
    Maurer, Hans H.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2018, 410 (03) : 897 - 912
  • [37] SINGLE-DOSE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF MK-0476, A NEW LEUKOTRIENE D-4-RECEPTOR ANTAGONIST, IN HEALTHY-VOLUNTEERS
    SCHOORS, DF
    DESMET, M
    REISS, T
    MARGOLSKEE, D
    CHENG, H
    LARSON, P
    AMIN, R
    SOMERS, G
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) : 277 - 280
  • [38] STEADY-STATE PHARMACOKINETICS OF A NEW 4-GRAM 5-AMINOSALICYLIC ACID RETENTION ENEMA IN PATIENTS WITH ULCERATIVE-COLITIS IN REMISSION
    ALMER, S
    NORLANDER, B
    STROM, M
    OSTERWALD, H
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 (03) : 327 - 335
  • [39] A New Antitumor Agent, (3-chloro-7-methoxyfuro[2,3-b]-quinolin-4-yl)-(4-methoxyphenyl)amine, Loaded in Solid Lipid Nanoparticles: Characterization and Pharmacokinetics
    Fang, Yi-Ping
    Wu, Pao-Chu
    Tzeng, Cherng-Chyi
    Chen, Yeh-Long
    Lin, Huei-Lan
    Tsai, Yi-Hung
    CURRENT NANOSCIENCE, 2012, 8 (02) : 266 - 273
  • [40] Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study
    Curtin, Francois
    Vidal, Virginie
    Bernard, Corinne
    Kromminga, Arno
    Lang, Alois B.
    Porchet, Herve
    MABS, 2016, 8 (05) : 854 - 860